Neurological Sciences

, Volume 30, Issue 1, pp 21–31

Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b

  • Carlo Lazzaro
  • Cosetta Bianchi
  • Lucia Peracino
  • Paola Zacchetti
  • Antonio Uccelli
Original Article

DOI: 10.1007/s10072-009-0015-0

Cite this article as:
Lazzaro, C., Bianchi, C., Peracino, L. et al. Neurol Sci (2009) 30: 21. doi:10.1007/s10072-009-0015-0

Abstract

New therapeutic options have modified the natural history and health care costs of multiple sclerosis (MS). An epidemiological 25 years-long model-based cost-utility analysis was performed following the Italian National Health Service (INHS) and societal perspectives to compare costs and quality-adjusted life years of treatment with Interferon β-1b (IFNB-1b) from diagnosis of clinically isolated syndrome (CIS) versus treating at subsequent conversion to clinically definite MS (CDMS). Among patients treated (untreated) with IFNB-1b from CIS diagnosis, 40,420 (43,700) converted to CDMS after 25 years; the estimated cumulative probability of converting to CDMS during the first 3 years was 72.90% (84.94%) (P < 0.0001). Early treatment with IFNB-1b is highly cost-effective for the INHS (incremental cost-effectiveness ratio: Euros 2,574.94) and dominant from the societal viewpoint. Sensitivity analyses confirmed the base case findings. Early treatment with IFNB-1b delays conversion to CDMS in CIS patients and might be a “good value for money” health care programme.

Keywords

CIS MS Interferon β-1b Cost-utility analysis 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Carlo Lazzaro
    • 1
  • Cosetta Bianchi
    • 2
  • Lucia Peracino
    • 2
  • Paola Zacchetti
    • 2
  • Antonio Uccelli
    • 3
  1. 1.Studio di Economia SanitariaMilanItaly
  2. 2.Bayer S.p.A., Bayer Schering PharmaMilanItaly
  3. 3.Department of Neurosciences, Ophthalmology and GeneticsUniversity of GenoaGenoaItaly

Personalised recommendations